Evidence mapPaperPMID 29121091Full record

Trial reportPloS one2017

Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension.

Timo P Hiltunen, Jenni M Rimpelä, Robert P Mohney, Steven M Stirdivant, Kimmo K Kontula

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719714 (Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05719714 phase1 / phase2active not recruitingstarted 2024, after this paper: background citation

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Ran2024Enrolled18Registered outcomes5Posted comparisons0ConditionsChronic Kidney Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Kidney DiseasesArmsDapagliflozin 10 MG [Farxiga]
Open the trial in the graph
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Urate-lowering effects of losartan: a meta-analysis of randomised controlled trials and target trial emulation.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Effect of Yishenjiangyafang on Plasma Metabolomics in Senile Spontaneously Hypertensive Rats.Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  10. Article
  11. Article
  12. Urbanization in China is associated with pronounced perturbation of plasma metabolites.Metabolomics : Official journal of the Metabolomic Society · 2020
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Timo P HiltunenDepartment of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0001-7011-0422
Jenni M RimpeläDepartment of Medicine, University of Helsinki, Helsinki, Finland.
Robert P MohneyMetabolon Inc., Durham, NC, United States of America.
Steven M StirdivantMetabolon Inc., Durham, NC, United States of America.
Kimmo K KontulaDepartment of Medicine, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIMetabolon (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn order to search for metabolic biomarkers of antihypertensive drug responsiveness, we measured >600 biochemicals in plasma samples of subjects participating in the GENRES Study. Hypertensive men received in a double-blind rotational fashion amlodipine, bisoprolol, hydrochlorothiazide and losartan, each as a monotherapy for one month, with intervening one-month placebo cycles.

methodsMetabolomic analysis was carried out using ultra high performance liquid chromatography-tandem mass spectrometry. Full metabolomic signatures (the drug cycles and the mean of the 3 placebo cycles) became available in 38 to 42 patients for each drug. Blood pressure was monitored by 24-h recordings.

resultsAmlodipine (P values down to 0.002), bisoprolol (P values down to 2 x 10-5) and losartan (P values down to 2 x 10-4) consistently decreased the circulating levels of long-chain acylcarnitines. Bisoprolol tended to decrease (P values down to 0.002) the levels of several medium- and long-chain fatty acids. Hydrochlorothiazide administration was associated with an increase of plasma uric acid level (P = 5 x 10-4) and urea cycle metabolites. Decreases of both systolic (P = 0.06) and diastolic (P = 0.04) blood pressure after amlodipine administration tended to associate with a decrease of plasma hexadecanedioate, a dicarboxylic fatty acid recently linked to blood pressure regulation.

conclusionsAlthough this systematic metabolomics study failed to identify circulating metabolites convincingly predicting favorable antihypertensive response to four different drug classes, it provided accumulating evidence linking fatty acid metabolism to human hypertension.

Indexed as

MetabolomicsAdultAntihypertensive AgentsDouble-Blind MethodEssential HypertensionFemaleHumansMaleMiddle AgedTreatment OutcomeAntihypertensive Agents

Identifiers

PMID29121091
PMCPMC5679533
OpenAlexW2768082288

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.